Final Results of a Phase II Study of Quizartinib in Patients with FLT3 ITD-Positive or Negative Relapsed/Refractory AML
Cortes JE et al. Final results of a Phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients ≥ 60 years of age with FLT3 ITD positive or negative relapsed/refractory acute myeloid leukemia. Proc ASH 2012;Abstract 48.
Levis M et al. Final results of a Phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia after second-line chemotherapy or hematopoietic stem cell transplantation. Proc ASH 2012;Abstract 673.
Dr Talpaz is Alexander J Trotman Professor of Leukemia Research, Associate Director of Translational Research at UM Comprehensive Cancer Center, Associate Chief of the Division of Hematology/Oncology and Director of Hematologic Malignancies at the University of Michigan Medical Center in Ann Arbor, Michigan.
|